- Author(s):
- Organization(s):
Aradigm
There are no approved controlled release inhalation products. Why is this? When might this situation change?
There is an opportunity for inhaled formulations to address other lung diseases for which there are inadequate alternatives; e.g., lung cancer and lung infections.